&nbsp;

Sep 2025

Regimen

ABIRPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Curative

Funding:

ODB - General Benefit

abiraterone

ODB - General Benefit

prednisone

Drugs Used:

abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

AZCTIVOS

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

New Drug Funding Program

Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Drugs Used:

ivosidenib,

azaCITIDine

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

zolbetuximab

Other Name(s): Vyloy®

Quick Link(s):

Sep 2025

Algorithmes de tests réflexifs de biomarqueurs du SNC

Guidelines and Advice

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Status: Current
ID: GL END 4-19

Updated

Nov 2025

Regimen

ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs Used:

zolbetuximab

Quick Link(s):

Regimen Monograph

Nov 2025

Drug

amivantamab

Other Name(s): Rybrevant®

Quick Link(s):

Updated

Nov 2025

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Nov 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

Exceptional Access Program

alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib